Tag: Vaccines

BNT162b2 vaccine effectiveness against symptomatic infection modest and declined rapidly, was higher after booster dose in teens

Estimated vaccine efficacy with two doses was 88.0 percent against COVID-19 at a time when delta was dominant circulating variant

Nearly 400 million doses of vaccine made by Emergent had to be destroyed 'due to poor quality control'

The phase 1 trial is expected to last four years and enroll 40 participants

With safer two-dose vaccines such as Pfizer and Moderna widely available, the one-dose J&J shot should be limited

Vaccine efficacy ranged from 69.5 percent against symptomatic infection to 78.8 percent against moderate-to-severe disease

27 percent said they would 'definitely not' get their child vaccinated, 11 percent said they would do so only if required

Stress surrounding the pandemic declined in U.S. children after vaccinations were rolled out for adults

COVID-19 vaccination is not associated with heart transplant-specific adverse events

Axillary lymphadenopathy more likely within 14 days after vaccination; persistent axillary lymphadenopathy seen up to 43 weeks later